Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
V-SARS Oral Therapeutic Vaccine for COVID-19
NCT04380532Phase 2Unknown
- Sponsor
- Immunitor Inc.
- Start
- May 2020
- Primary completion
- May 2021
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 2
01
Overview
Phase 2, open-label, single-arm trial of Immunitor COVID-19 vaccine in coronavirus disease 2019 (COVID-19), sponsored by Immunitor Inc. Primary endpoints: Effect on Complete Blood Count at 15 days and Effect on biochemistry parameters at 15 days. Status: unknown.
02
Drugs
Immunitor COVID-19 vaccine
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04380532.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04380532.